A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: a phase II study group trial of the Central European Society of Anticancer-Drug Research (CESAR).
R.D. Hofheinz,Camillo Porta,G. Hartung,Armando Santoro,A.-R. Hanauske,K. Kutz,A. Stern,P. Barbieri,E. Verdi,Ruediger Hehlmann,Andreas Hochhaus +10 more
TL;DR: The feasibility and tolerability of BBR 3438 applied at a dose of 50 mg/m2 four-weekly as an 1-hour infusion to pretreated patients with gastric cancer was confirmed and neither relevant LVEF decreases nor hints of cardiac toxicity were observed.
Journal ArticleDOI
Results of the randomized phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients (pts) with translocation-related sarcoma (TRS).
Andrew Eugene Hendifar,Sant P. Chawla,Michael G Leahy,Antoine Italiano,Shreyaskumar Patel,Armando Santoro,Arthur P. Staddon,Nicolas Penel,Sophie Piperno-Neumann,George D. Demetri,Larry Hayward,Jeff White,Launce G. Gouw,Bernardo De Miguel,Pilar Lardelli,Arturo Soto,Antonio Nieto,Jean-Yves Blay +17 more
TL;DR: T is the first of a new class of anticancer agents with a transcription-targeted mechanism of action that interferes with the aberrant transcription factors binding to DNA promoters in TRS.
Journal ArticleDOI
Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.
Kohei Shitara,Toshihiko Doi,Hisashi Hosaka,Peter C. Thuss-Patience,Armando Santoro,Paula Jiménez-Fonseca,Federico Longo,Ozgur Ozyilkan,Irfan Cicin,David C. Park,Mohamedtaki Abdulaziz Tejani,Aziz Zaanan,Domenico Bilancia,Carles Pericay,Mustafa Ozguroglu,Maria Alsina,Lukas Makris,Sandra McGuigan,David H. Ilson +18 more
TL;DR: The global phase 3 study TAGS (NCT02500043) demonstrated the efficacy and safety of FTD/TPI in prev...
Journal ArticleDOI
Safety of autologous fat grafting in breast cancer: a multicenter Italian study among 17 senonetwork breast units autologous fat grafting safety: a multicenter Italian retrospective study
Marco Klinger,Agnese Losurdo,Andrea Lisa,Emanuela Morenghi,Valeriano Vinci,Fabio Corsi,Sara Albasini,Maria Cristina Leonardi,Barbara Alicja Jereczek-Fossa,Barbara Alicja Jereczek-Fossa,Paolo Veronesi,Paolo Veronesi,Mario Rietjens,Luca Fabiocchi,Sonia Santicchia,Francesco Klinger,Andrea Loreti,Lucio Fortunato,Maria Alessandra Bocchiotti,Fulvio A. Nicolò,Paolo Stringhini,Pier Camillo Parodi,Emanuele Rampino,Valentina Guarneri,Giulia Pagura,Erica Dalla Venezia,Graziano Meneghini,Tanja Kraljic,Paolo Persichetti,Mauro Barone,Nicola Vaia,Irene Zerini,Luca Grimaldi,Michele Riccio,Angelica Aquinati,Franco Bassetto,Vincenzo Vindigni,Luigi Ciuffreda,Corrado Tinterri,Armando Santoro +39 more
TL;DR: In this article, a large-scale multicenter cohort of early breast cancer patients from 17 Italian Breast Units was collected and compared with patients who did not undergo autologous fat grafting.
Journal ArticleDOI
Results of a phase II clinical trial to evaluate a re-challenge of intraperitoneal catumaxomab for treatment of malignant ascites (MA) due to epithelial cancer (SECIMAS).
Klaus Pietzner,Ignace Vergote,Armando Santoro,Frederik Marmé,Per Rosenberg,Hilke Friccius-Quecke,Jalid Sehouli +6 more
TL;DR: A re-challenge is feasible and effective despite the immunogenicity of this non-humanised antibody for the i.p. treatment of MA, and 8 out of 9 screened pts were treated with a second cycle of catumaxomab.